Daisuke Kato
Astellas Pharma
Janus kinaseInternal medicineRandomized controlled trialSystematic reviewAdverse effectRheumatologyJanus kinase inhibitorRheumatoid arthritisTofacitinibPeficitinib2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Extension studyMedicineMeta-analysis
2Publications
0Citations
Publications 2
Newest
#1Tsutomu Takeuchi (Keio: Keio University)H-Index: 84
#2Yoshiya TanakaH-Index: 92
Last. Daisuke Kato (Astellas Pharma)
view all 7 authors...
To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [dat...
Source
#1Yoshiya Tanaka (University of Occupational and Environmental Health Japan)H-Index: 92
#2Hiroyuki Okumura (Astellas Pharma)H-Index: 3
Last. Neil M. Schultz (CGD: Center for Global Development)
view all 8 authors...
Peficitinib, a Janus kinase (JAK) inhibitor, is approved for clinical use in Japan, Korea, and Taiwan, but head-to-head comparisons versus other JAK inhibitors are lacking. We indirectly compared peficitinib, tofacitinib, and baricitinib for rheumatoid arthritis treatment. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and congress archives up until February 12, 2019, for randomized controlled trials of peficitinib, tofacitinib, and baricitin...
Source